Author

J. F. Amatruda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Organism:human· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Marchetto· 1 shared C. Arrigoni· 1 shared D. Saucier· 1 shared E. Vasileva· 1 shared F. Cidre-Aranaz· 1 shared F. S. Wehweck· 1 shared G. Sannino· 1 shared J. Li· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Marchetto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMay 25, 2021

Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth

E. Vasileva, M. Warren, T. J. Triche, J. F. Amatruda

This study develops a zebrafish model of Ewing sarcoma and identifies heparan sulfate proteoglycan metabolism as a driver of tumor growth, showing that targeting this pathway reduces tumorigenicity.

DOI 10.7554/elife.69734

zebrafishproteomics

𝕏 PostBluesky

Cancer BiologybioRxivMar 14, 2019

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

A. Marchetto, S. Ohmura, M. F. Orth…·T. G. P. Grunewald

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

DOI 10.1038/s41467-020-16244-2

humanbulk RNA-seq

𝕏 PostBluesky